Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Eli Lilly & Co., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2025 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial performance concerning economic value creation exhibits a distinct U-shaped trajectory from 2021 to 2025. After a period of contraction between 2021 and 2023, there is a substantial acceleration in value generation during the 2024 and 2025 periods, characterized by an exponential increase in economic profit.

Net Operating Profit After Taxes (NOPAT)
A downward trend in NOPAT is observed from 2021 to 2023, with values decreasing from 5,065 million US$ to 3,228 million US$. This contraction is followed by a sharp reversal; NOPAT increases significantly to 8,605 million US$ in 2024 and reaches 19,711 million US$ by 2025. The growth rate in the final two years suggests a substantial increase in operational efficiency or a significant expansion in revenue streams.
Invested Capital and Cost of Capital
Invested capital shows a slight decrease in 2022 before entering a phase of consistent expansion, growing from 24,287 million US$ in 2022 to 49,610 million US$ by 2025. Parallel to this growth in capital deployment, the cost of capital remains relatively stable, fluctuating within a narrow range between 8.97% and 9.34%. This indicates that the increased investment was achieved without a significant escalation in the weighted average cost of financing.
Economic Profit Analysis
Economic profit declined sharply from 2,723 million US$ in 2021 to a low of 489 million US$ in 2023, reflecting a period where the growth in operating profit failed to keep pace with the capital charge. However, a pivot occurs in 2024, with economic profit rising to 5,273 million US$, and further surging to 15,076 million US$ in 2025. The magnitude of this increase demonstrates that NOPAT growth far exceeded the incremental cost of the additional invested capital, resulting in significant shareholder value creation.

Net Operating Profit after Taxes (NOPAT)

Eli Lilly & Co., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net income
Deferred income tax expense (benefit)1
Increase (decrease) in LIFO reserve2
Increase (decrease) in equity equivalents3
Interest expense on borrowings
Interest expense, operating lease liability4
Adjusted interest expense on borrowings
Tax benefit of interest expense on borrowings5
Adjusted interest expense on borrowings, after taxes6
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in LIFO reserve. See details »

3 Addition of increase (decrease) in equity equivalents to net income.

4 2025 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2025 Calculation
Tax benefit of interest expense on borrowings = Adjusted interest expense on borrowings × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net income.


Net income and net operating profit after taxes (NOPAT) exhibited distinct trends over the five-year period. While net income generally increased, NOPAT demonstrated a more complex pattern of fluctuation.

NOPAT Trend
NOPAT decreased from US$5,065 million in 2021 to US$3,228 million in 2023, representing a substantial decline over two years. This downward trend reversed in 2024, with NOPAT increasing significantly to US$8,605 million. The most substantial growth occurred between 2024 and 2025, with NOPAT reaching US$19,711 million. This indicates a considerable improvement in core operational profitability in the latter part of the period.
Relationship between Net Income and NOPAT
Although both metrics generally moved in the same direction, the magnitude of change differed. Net income increased from US$5,582 million in 2021 to US$6,245 million in 2022, then decreased to US$5,240 million in 2023, before experiencing substantial growth in 2024 and 2025, reaching US$20,640 million. The difference between net income and NOPAT suggests that factors beyond core operations, such as financing costs or non-operating income, played an increasingly significant role in determining overall net income, particularly in 2024 and 2025.

The substantial increase in NOPAT from 2023 to 2025 suggests improved operational efficiency, increased sales volume, or a combination of both. Further investigation would be required to determine the specific drivers of this improvement. The divergence between net income and NOPAT trends warrants further scrutiny to understand the impact of non-operating items on overall profitability.


Cash Operating Taxes

Eli Lilly & Co., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Income taxes
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense on borrowings
Cash operating taxes

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


A significant increase in both income taxes and cash operating taxes is observed over the five-year period. While income taxes demonstrate substantial growth, cash operating taxes exhibit a more pronounced and consistent upward trajectory.

Income Taxes
Income taxes remained relatively stable between 2021 and 2022, fluctuating between US$562 million and US$574 million. A substantial increase is then noted in 2023, reaching US$1,314 million, followed by further increases to US$2,090 million in 2024 and US$5,091 million in 2025. This represents a nearly nine-fold increase over the 2021 level.
Cash Operating Taxes
Cash operating taxes demonstrate a consistent upward trend throughout the period. Beginning at US$1,452 million in 2021, they more than doubled to US$2,822 million in 2022. Continued growth is evident in subsequent years, reaching US$3,767 million in 2023, US$4,949 million in 2024, and US$6,999 million in 2025. This represents a nearly five-fold increase over the 2021 level.
Relationship between Income Taxes and Cash Operating Taxes
While both metrics increase, cash operating taxes consistently exceed income taxes throughout the observed period. The difference between the two widens over time, suggesting increasing tax payments beyond the reported income tax expense. This divergence could be attributable to various factors, including timing differences between accounting and cash tax liabilities, changes in tax regulations, or the utilization of tax loss carryforwards. The substantial growth in cash operating taxes, particularly in the later years, warrants further investigation to understand the underlying drivers and potential implications for future cash flows.

The observed trends suggest a growing tax burden for the company. The significant increase in cash operating taxes, exceeding the growth in reported income taxes, indicates a potential shift in the company’s tax profile and requires further scrutiny.


Invested Capital

Eli Lilly & Co., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Short-term borrowings and current maturities of long-term debt
Long-term debt, excluding current maturities
Operating lease liability1
Total reported debt & leases
Total Eli Lilly and Company shareholders’ equity
Net deferred tax (assets) liabilities2
LIFO reserve3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Noncontrolling interests
Adjusted total Eli Lilly and Company shareholders’ equity
Construction in progress6
Marketable securities7
Invested capital

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of LIFO reserve. See details »

4 Addition of equity equivalents to total Eli Lilly and Company shareholders’ equity.

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of marketable securities.


The reported invested capital exhibited a fluctuating pattern over the five-year period. Total reported debt & leases and total shareholders’ equity both contributed to the overall invested capital figure, with notable changes observed in both components.

Invested Capital Trend
Invested capital decreased from US$26,117 million in 2021 to US$24,287 million in 2022, representing a decline of approximately 6.7%. Subsequently, invested capital increased to US$29,370 million in 2023, US$35,786 million in 2024, and further to US$49,610 million in 2025. This indicates a substantial growth trend in invested capital from 2022 through 2025.
Debt & Leases
Total reported debt & leases decreased from US$17,570 million in 2021 to US$16,967 million in 2022. However, beginning in 2023, a consistent and significant increase in debt & leases is observed, rising to US$26,330 million, US$34,791 million, and ultimately US$43,865 million in 2025. This represents a considerable reliance on debt financing over the latter part of the analyzed period.
Shareholders’ Equity
Total shareholders’ equity demonstrated an initial increase from US$8,979 million in 2021 to US$10,650 million in 2022, and a slight increase to US$10,772 million in 2023. A more pronounced growth in shareholders’ equity is then evident in 2024 and 2025, reaching US$14,192 million and US$26,535 million respectively. This suggests increasing internal funding sources alongside the growing debt levels.

The combined effect of increasing debt and shareholders’ equity resulted in the overall upward trend in invested capital from 2022 onwards. The rate of increase in invested capital accelerated in the later years, driven primarily by the substantial growth in both debt and equity financing.


Cost of Capital

Eli Lilly & Co., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2025-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Eli Lilly & Co., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2025 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial trajectory concerning value creation exhibits a distinct V-shaped recovery, characterized by a period of contraction followed by aggressive expansion. Between 2021 and 2023, there was a marked decline in economic efficiency and value generation, which was subsequently reversed by an exponential increase in profitability and capital productivity through 2025.

Economic Profit Trends
Economic profit experienced a significant downward trend from 2021 to 2023, falling from US$ 2,723 million to a low of US$ 489 million. This decline was followed by a rapid recovery in 2024, where profit climbed to US$ 5,273 million, and culminated in a substantial surge to US$ 15,076 million by December 31, 2025.
Invested Capital Dynamics
Invested capital remained relatively stable during the initial period, with a slight decrease from US$ 26,117 million in 2021 to US$ 24,287 million in 2022. Starting in 2023, a consistent upward trend in capital allocation is observed, with the amount rising to US$ 29,370 million, then to US$ 35,786 million in 2024, and finally reaching US$ 49,610 million in 2025.
Economic Spread Ratio Analysis
The economic spread ratio indicates a period of severe compression in value creation, dropping from 10.42% in 2021 to a minimum of 1.66% in 2023, suggesting that returns were only marginally above the cost of capital. A sharp reversal occurred in 2024 as the ratio rose to 14.74%, followed by a dramatic increase to 30.39% by 2025. This trend demonstrates that profitability grew at a much faster rate than the growth of invested capital, leading to a significant improvement in the overall economic spread.

The correlation between the expanding capital base and the surging economic spread ratio suggests a highly successful scaling operation. The ability to increase invested capital by approximately 104% from 2022 to 2025 while simultaneously increasing the economic spread ratio from 8.76% to 30.39% reflects an exceptional increase in the efficiency of capital deployment.


Economic Profit Margin

Eli Lilly & Co., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Economic profit1
Revenue
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Economic profit. See details »

2 2025 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenue
= 100 × ÷ =

3 Click competitor name to see calculations.


The financial performance between 2021 and 2025 is characterized by a significant U-shaped trajectory in economic profitability, coinciding with an aggressive acceleration in revenue growth.

Economic Profit Margin Trends
A contraction in the economic profit margin is observed from 2021 to 2023, falling from 9.61% to a period low of 1.43%. This decline indicates a narrowing gap between the return on invested capital and the company's cost of capital during this interval. However, a sharp reversal occurred in 2024 and 2025, with the margin expanding rapidly to 11.71% and 23.13%, respectively, representing a substantial increase in value creation relative to revenue.
Revenue Growth Trajectory
Revenue exhibited consistent upward momentum throughout the period. While growth was modest between 2021 and 2022, it accelerated significantly starting in 2023. Revenue increased from 28,318 million US$ in 2021 to 65,179 million US$ by 2025, indicating a strong expansion of market scale.
Economic Profit Analysis
Economic profit mirrored the margin trends, experiencing a steep decline from 2,723 million US$ in 2021 to 489 million US$ in 2023. This suggests that despite increasing revenues in 2023, the capital charges or operational costs grew at a rate that nearly offset the nominal profits. Following this trough, economic profit grew exponentially, reaching 15,076 million US$ by 2025, which signifies a period of highly efficient capital utilization and scaled profitability.

The divergence observed in 2023, where revenue increased while economic profit and margins plummeted, suggests a phase of heavy investment or increased capital costs. The subsequent surge in both revenue and economic profit margin through 2025 indicates that these prior investments successfully transitioned into high-margin returns, resulting in an optimized economic value added profile.